{"transactions":[{"id":1007688,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-11-05T21:17:44.000Z","date":"2025-11-03","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028."}],"balance_after":8500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0000905148-25-003784","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825003784/form4.xml","form_type":"4"}},{"id":1258180,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-02-21T02:07:48.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs, which vested on July 17, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs, which vested on July 17, 2024."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0000905148-25-000739","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000739/form4.xml","form_type":"4"}},{"id":1258179,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-02-21T02:07:48.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8500,"source":{"system":"sec-edgar","filing":"0000905148-25-000739","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000090514825000739/form4.xml","form_type":"4"}},{"id":1811416,"issuer":{"id":7495,"kind":"organization","name":"CEL SCI CORP"},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options","published_at":"2023-08-10T20:53:23.000Z","date":"2023-08-08","kind":"grant","planned":false,"acquired":true,"shares":85000,"price":0.01,"value":850.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest in three (3) equal annual installments commencing one year after the grant date."}],"balance_after":149000,"derivative":{"exercise_price":1.36,"expiration_date":"2033-08-07","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001236030-23-000014","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/725363/000123603023000014/primary_doc.xml","form_type":"4"}},{"id":1827475,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-07-19T21:28:26.000Z","date":"2023-07-17","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on July 17, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on July 17, 2024."}],"balance_after":8500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001209191-23-042765","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919123042765/doc4.xml","form_type":"4"}},{"id":2092864,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-09T01:10:19.000Z","date":"2022-12-07","kind":"sale","acquired":false,"shares":3922,"price":5.2614,"value":20635.2108,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.20 to $5.31, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-060424","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122060424/doc4.xml","form_type":"4"}},{"id":2148451,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-10-03T22:38:40.000Z","date":"2022-09-29","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the Issuer.  The RSU's will vest on September 29, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock of the Issuer.  The RSU's will vest on September 29, 2023."}],"balance_after":5000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-22-051960","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122051960/doc4.xml","form_type":"4"}},{"id":2177784,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-08-22T10:00:54.000Z","date":"2022-08-18","kind":"exercise","acquired":false,"shares":1984,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 18, 2022, the reporting person received 1,984 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on July 1, 2022."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vested on July 1, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vested on July 1, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On August 18, 2022, the reporting person received 1,984 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on July 1, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1984},"source":{"system":"sec-edgar","filing":"0001209191-22-046968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122046968/doc4.xml","form_type":"4"}},{"id":2177783,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-22T10:00:54.000Z","date":"2022-08-18","kind":"exercise","acquired":true,"shares":1984,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 18, 2022, the reporting person received 1,984 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on July 1, 2022."}],"balance_after":3922,"source":{"system":"sec-edgar","filing":"0001209191-22-046968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000120919122046968/doc4.xml","form_type":"4"}},{"id":2606322,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-08-13T01:39:17.000Z","date":"2021-08-10","kind":"exercise","acquired":false,"shares":96864,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each RSU represented a contingent right to receive one share of issuer common stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vested on June 18, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vested on June 18, 2021."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each RSU represented a contingent right to receive one share of issuer common stock upon settlement."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":96864},"source":{"system":"sec-edgar","filing":"0001387131-21-008441","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121008441/ownership.xml","form_type":"4"}},{"id":2606321,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-13T01:39:17.000Z","date":"2021-08-10","kind":"exercise","acquired":true,"shares":96864,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021."}],"balance_after":96864,"source":{"system":"sec-edgar","filing":"0001387131-21-008441","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121008441/ownership.xml","form_type":"4"}},{"id":2646988,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-07-02T22:04:56.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":99174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on July 1, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on July 1, 2022."}],"balance_after":99174,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":99174},"source":{"system":"sec-edgar","filing":"0001387131-21-007131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121007131/ownership.xml","form_type":"4"}},{"id":2905728,"issuer":{"id":112047,"kind":"organization","name":"Histogen Inc.","symbol":"HSTO"},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-15T16:14:23.000Z","date":"2021-01-13","kind":"grant","acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4 of the shares subject to the option vest one year after the date of grant, on 1/13/2022, and the remaining 1/36 of the shares vest on a monthly basis thereafter."}],"balance_after":95000,"derivative":{"exercise_price":0.97,"expiration_date":"2031-01-13","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0001209191-21-003758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1297506/000120919121003758/doc4.xml","form_type":"4"}},{"id":3104963,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-19T21:10:04.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":96864,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on June 18, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on June 18, 2021."}],"balance_after":96864,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":96864},"source":{"system":"sec-edgar","filing":"0001387131-20-005819","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713120005819/ownership.xml","form_type":"4"}},{"id":3131985,"issuer":{"id":112047,"kind":"organization","name":"Histogen Inc.","symbol":"HSTO"},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2020-05-28T19:55:22.000Z","date":"2012-05-12","kind":"other","acquired":true,"shares":380063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Fully vested. Shares subject to the option and the exercise price have been adjusted based upon the Conversion and Reverse Split."}],"balance_after":380063,"derivative":{"exercise_price":0.53,"expiration_date":"2022-05-12","underlying":"Common Stock","underlying_shares":380063},"source":{"system":"sec-edgar","filing":"0000899243-20-014479","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1297506/000089924320014479/doc4.xml","form_type":"4"}},{"id":3131984,"issuer":{"id":112047,"kind":"organization","name":"Histogen Inc.","symbol":"HSTO"},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-05-28T19:55:22.000Z","date":"2020-05-26","kind":"other","acquired":true,"shares":426526,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"timeliness","element":"transactionTimeliness","label":"F1","text":"Shares of common stock of the corporation formerly known as Histogen Inc. (\"Histogen\") were converted into shares of common stock of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of January 28, 2020, by and among the Issuer, Chinook Merger Sub, Inc. and Histogen (the \"Merger Agreement\"). Pursuant to the terms of the Merger Agreement, each share of Histogen common stock was exchanged for 1.4342 shares of the Issuer's common stock (the \"Conversion\"). Immediately following the merger, the Issuer changed its name to Histogen Inc. All share numbers reflect the one-for-ten reverse stock split (the \"Reverse Split\") effected by the Issuer immediately prior to the completion of the merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by the Gail K. Naughton Revocable Trust, dated January 19, 2018."}],"balance_after":426526,"source":{"system":"sec-edgar","filing":"0000899243-20-014479","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1297506/000089924320014479/doc4.xml","form_type":"4"}},{"id":4116443,"issuer":{"id":170698,"kind":"organization","name":"BARD C R INC /NJ/","symbol":"BCR"},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true}}],"security":"Share Equivalent Units","published_at":"2018-01-03T18:33:56.000Z","date":"2017-12-29","kind":"disposition_to_issuer","acquired":false,"shares":9516,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Units granted under the Company's Stock Equivalent Plan for Outside Directors."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Conversion is 1 for 1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These units, which are 100% vested, were assumed by BD at the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These units, which are 100% vested, were assumed by BD at the effective time of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These units, which are 100% vested, were assumed by BD at the effective time of the Merger."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9516},"source":{"system":"sec-edgar","filing":"0001225208-18-000469","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/9892/000122520818000469/doc4.xml","form_type":"4"}},{"id":4116442,"issuer":{"id":170698,"kind":"organization","name":"BARD C R INC /NJ/","symbol":"BCR"},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-01-03T18:33:56.000Z","date":"2017-12-29","kind":"disposition_to_issuer","acquired":false,"shares":1922.6298,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the \"Merger\") of Lambda Corp. (\"Lambda\") with and into C. R. Bard, Inc. (\"Bard\") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company (\"BD\") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001225208-18-000469","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/9892/000122520818000469/doc4.xml","form_type":"4"}},{"id":4143816,"issuer":{"id":170698,"kind":"organization","name":"BARD C R INC /NJ/","symbol":"BCR"},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true}}],"security":"Share Equivalent Units","published_at":"2017-12-05T15:05:42.000Z","date":"2017-12-04","kind":"grant","acquired":true,"shares":245,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Units granted under the Company's Stock Equivalent Plan for Outside Directors."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Conversion is 1 for 1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Share Equivalent Units are settled in cash upon termination as a director."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Share Equivalent Units are settled in cash upon termination as a director."}],"balance_after":9516,"derivative":{"underlying":"Common Stock","underlying_shares":245},"source":{"system":"sec-edgar","filing":"0001225208-17-018191","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/9892/000122520817018191/doc4.xml","form_type":"4"}},{"id":4143815,"issuer":{"id":170698,"kind":"organization","name":"BARD C R INC /NJ/","symbol":"BCR"},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true}}],"security":"Common Stock","published_at":"2017-12-05T15:05:42.000Z","date":"2017-12-04","kind":"grant","acquired":true,"shares":298,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Stock award granted in accordance with the 2005 Directors' Stock Award Plan, as amended and restated, that fully vests in three years from the date of grant, subject to earlier acceleration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4.87 shares acquired under the Company's Dividend Reinvestment Plan from November 5, 2016 to August 4, 2017."}],"balance_after":1922.6298,"source":{"system":"sec-edgar","filing":"0001225208-17-018191","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/9892/000122520817018191/doc4.xml","form_type":"4"}},{"id":4149411,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2017-11-29T22:39:06.000Z","date":"2017-11-28","kind":"other","acquired":true,"shares":1800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the \"Company\") to all holders of the Company's common stock on October 27, 2017.  The subscription rights entitled each recipient to purchase units (\"Units\").  Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock.  The purchase price for each Unit was $1,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020."}],"balance_after":1800,"derivative":{"exercise_price":0.3333,"expiration_date":"2020-05-28","underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0001209191-17-062901","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919117062901/doc4.xml","form_type":"4"}},{"id":4149410,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2017-11-29T22:39:06.000Z","date":"2017-11-28","kind":"other","acquired":true,"shares":1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the \"Company\") to all holders of the Company's common stock on October 27, 2017.  The subscription rights entitled each recipient to purchase units (\"Units\").  Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock.  The purchase price for each Unit was $1,000."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Preferred Stock has no expiration date."}],"balance_after":1,"derivative":{"exercise_price":0.3333,"exercise_date":"2017-11-28","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-17-062901","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919117062901/doc4.xml","form_type":"4"}},{"id":4149409,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Subscription Rights (Right to Buy)","published_at":"2017-11-29T22:39:06.000Z","date":"2017-11-28","kind":"other","acquired":false,"shares":1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the \"Company\") to all holders of the Company's common stock on October 27, 2017.  The subscription rights entitled each recipient to purchase units (\"Units\").  Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock.  The purchase price for each Unit was $1,000."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the \"Company\") to all holders of the Company's common stock on October 27, 2017.  The subscription rights entitled each recipient to purchase units (\"Units\").  Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock.  The purchase price for each Unit was $1,000."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the \"Company\") to all holders of the Company's common stock on October 27, 2017.  The subscription rights entitled each recipient to purchase units (\"Units\").  Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock.  The purchase price for each Unit was $1,000."}],"balance_after":0,"derivative":{"exercise_price":1000,"exercise_date":"2017-11-02","expiration_date":"2017-11-21","underlying":"see footnote"},"source":{"system":"sec-edgar","filing":"0001209191-17-062901","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919117062901/doc4.xml","form_type":"4"}},{"id":4474894,"issuer":{"id":170698,"kind":"organization","name":"BARD C R INC /NJ/","symbol":"BCR"},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true}}],"security":"Common Stock","published_at":"2017-02-01T09:31:42.000Z","date":"2017-01-31","kind":"sale","acquired":false,"shares":367,"price":236.224,"value":86694.208,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sales price for price increments ranging from $236.17 to $236.35. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4."}],"balance_after":1619.7598,"source":{"system":"sec-edgar","filing":"0001225208-17-002153","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/9892/000122520817002153/doc4.xml","form_type":"4"}},{"id":4479561,"issuer":{"id":7637,"kind":"organization","name":"CERENOME, INC."},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-01-27T22:48:08.000Z","date":"2017-01-26","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reporting person received a non-qualified stock option granted under the Issuer's 2014 Equity Incentive Plan.  The exercise price per share to be paid by the reporting person at the time the option is exercised is the closing sale price of the Issuer's Common Stock on the NASDAQ Stock Market as of the date of the grant.  The closing sale price on the date of the grant was $1.56."}],"balance_after":25000,"derivative":{"exercise_price":1.56,"exercise_date":"2018-01-26","expiration_date":"2027-01-26","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-17-005972","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1095981/000120919117005972/doc4.xml","form_type":"4"}},{"id":4521738,"issuer":{"id":170698,"kind":"organization","name":"BARD C R INC /NJ/","symbol":"BCR"},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true}}],"security":"Share Equivalent Units","published_at":"2016-12-15T15:58:44.000Z","date":"2016-12-14","kind":"grant","acquired":true,"shares":375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Units granted under the Company's Stock Equivalent Plan for Outside Directors."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Conversion is 1 for 1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Share Equivalent Units are settled in cash upon termination as a director."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Share Equivalent Units are settled in cash upon termination as a director."}],"balance_after":9271,"derivative":{"underlying":"Common Stock","underlying_shares":375},"source":{"system":"sec-edgar","filing":"0001225208-16-043312","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/9892/000122520816043312/doc4.xml","form_type":"4"}},{"id":4521737,"issuer":{"id":170698,"kind":"organization","name":"BARD C R INC /NJ/","symbol":"BCR"},"owners":[{"id":73614,"kind":"person","name":"Naughton Gail K","position":1,"cik":"0001297506","reported_name":"Naughton Gail K","relationship":{"director":true}}],"security":"Common Stock","published_at":"2016-12-15T15:58:44.000Z","date":"2016-12-14","kind":"grant","acquired":true,"shares":468,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Stock award granted in accordance with the 2005 Directors' Stock Award Plan, as amended and restated, that fully vests in three years from the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 7.9533 shares acquired under the Company's Dividend Reinvestment Plan from November 7, 2015 to November 4, 2016."}],"balance_after":1986.7598,"source":{"system":"sec-edgar","filing":"0001225208-16-043312","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/9892/000122520816043312/doc4.xml","form_type":"4"}}]}